A related editorial says that based on these results, clinicians should continue to consider beta-blockers to be the primary medical therapy for aortic protection in Marfan's syndrome. Losartan appears to be a reasonable treatment option, especially where beta-blockers are unsuitable, but its efficacy needs to be firmly established before it becomes a first-line therapy.